SCHEMBL23086205

SCHEMBL23086205

CCC(C)[C@H](NC(=O)CNC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
LMNA P02545 1/20 0.60
CTSL P07711 3/20 0.60
CTSS P25774 3/20 0.60
CTSB P07858 2/20 0.60
MME P08473 1/20 0.54
ECE1 P42892 1/20 0.54
CYP3A4 P08684 2/20 0.53
CTSK P43235 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
RAB9A P51151 1/20 0.53
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 1/20 0.49
CASP3 P42574 1/20 0.48
ANPEP P15144 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23086206 1.00 MEN1 (0.60) MEN1KMT2ALMNACTSLCTSS
SCHEMBL23086208 1.00 MEN1 (0.60) MEN1KMT2ALMNACTSLCTSS
SCHEMBL4582904 0.89 MAPK1 (0.53) MEN1KMT2ALMNACTSLCTSS
SCHEMBL4582911 0.89 MAPK1 (0.53) MEN1KMT2ALMNACTSLCTSS
SCHEMBL919245 0.89 MAPK1 (0.53) MEN1KMT2ALMNACTSLCTSS
SCHEMBL24734375 0.87 CTSL (0.71) MEN1KMT2ALMNACTSLCTSS
SCHEMBL221435 0.87 CTSL (0.71) MEN1KMT2ALMNACTSLCTSS
SCHEMBL5145628 0.87 CTSL (0.71) MEN1KMT2ALMNACTSLCTSS
SCHEMBL7264750 0.87 CTSL (0.71) MEN1KMT2ALMNACTSLCTSS
SCHEMBL8837344 0.87 CTSL (0.71) MEN1KMT2ALMNACTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4077353-B1 SYNTHESIS OF AMANIN AND ITS DERIVATIVES HEIDELBERG PHARMA RES GMBH (DE) 2025-04-23 EP disclosed
US-20230039142-A1 SYNTHESIS OF AMANIN AND ITS DERIVATIVES HEIDELBERG PHARMA RESEARCH GMBH (DE) 2023-02-09 US disclosed
EP-4077353-A1 SYNTHESIS OF AMANIN AND ITS DERIVATIVES Heidelberg Pharma Research GmbH (DE) 2022-10-26 EP disclosed
US-20220298204-A1 SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES PURE BIOORGANICS SIA (LV) 2022-09-22 US disclosed
WO-2021122744-A1 SYNTHESIS OF AMANIN AND ITS DERIVATIVES HEIDELBERG PHARMA RESEARCH GMBH (DE) 2021-06-24 WO disclosed
EP-3792250-A1 SYNTHESIS OF ALPHA-AMANITIN AND ITS DERIVATIVES Pure Bioorganics SIA (LV) 2021-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298204-A1 SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES MEP1A, MEP1B, MANBA MEN1 124/4885KMT2A 2218/4885LMNA 2039/4885
US-20230039142-A1 SYNTHESIS OF AMANIN AND ITS DERIVATIVES AANAT, TYR, CIAPIN1 MEN1 15/4885KMT2A 1468/4885LMNA 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.